Uloric Injury & FDA Black Box Warning - The Lyon Firm
« Back to Blog

Uloric Injury & FDA Black Box Warning

The Food and Drug Administration warns Uloric (Febuxostat) may cause cardiac injuries and increases the risk of death in gout patients. Contact a Pharmaceutical attorney and Uloric Lawyer following any drug-related injury.


An urgent warning from the FDA notes specific cardiovascular risks for gout patients prescribed Uloric (febuxostat). According to the new boxed warning, medication guide and statements from the U.S. Food and Drug Administration, Uloric poses serious risks compared to the gout medication Allopurinol. The study concluded that “All-cause mortality and cardiovascular mortality were higher with febuxostat than with allopurinol. “

The FDA Uloric Injury warnings result from a safety clinical trial that found an increased risk of cardiovascular death with Uloric use. Uloric was first FDA-approved in 2009 to treat gout. Gout affects around 8 million adults in the U.S. Gout occurs when uric acid builds up and causes uncomfortable arthritic swelling and pain in the joints. Uloric (febuxostat), a Takeda Pharmaceutical, is meant to lower uric acid levels in the blood.

Joe Lyon is an experienced Drug Injury Lawyer engaging pharmaceutical companies nationwide in Uloric injury and wrongful death cases. Contact The Lyon Firm following any Uloric injury or serious complication.


Cardiovasular Uloric Injury & Death

It is critical for gout patients to inform health care professionals about any history of cardiac issues, including strokes or high blood pressure before taking Uloric (febuxostat). Patient should discontinue their medication and contact their physician if they experience any of the following symptoms:

  • Chest pain
  • Trouble Breathing
  • Irregular heartbeat
  • Numbness or weakness
  • Dizziness & Fatigue
  • Difficulty talking
  • Severe headache

Cardiac Injury & Uloric Lawsuits

Studies concluded that Uloric use may result in cardiovascular death, nonfatal myocardial infarction, stroke or angina. Febuxostat was associated with a 34 percent higher rate of death from cardiovascular causes than the other gout alternative, allopurinol.

Takeda Pharmaceuticals, the manufacturer of Uloric is facing product liability and personal injury claims, as well as whistleblower lawsuits that allege the company withheld information about dangerous side effects, including drug interactions, kidney problems, liver damage, and potential cardiac injury.

If you or a loved one has suffered an injury or premature death due to Uloric Injury, and have questions about the legal remedies available to improve quality of life and medical care, contact The Lyon Firm at (800) 513-2403. You will speak directly with Mr. Lyon, a drug injury lawyer, and he will help you answer critical questions regarding Uloric lawsuits.

Contact us today.